Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study.-MedSci.cn

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study.

Lopes, G; Wu, YL; Kudaba, I; Kowalski, D; Cho, BC; Castro, G; Srimuninnimit, V; Bondarenko, I; Kubota, K; Lubiniecki, GM; Zhang, J; Kush, DA; Mok, T

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (18):

科室
- - 订阅+
  - 更多科室
工具
服务